Clinical trial · Observational
Risk Factors and Long-term Impact of ICIs
To Evaluate the Prognostic Risk Factors and Long-term Health Effects of Immunotherapy Patients Based on the Specific Disease Cohort Registered With Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study plans to conduct a multicenter, observable and controlled cohort study to solid-tumor patients with receiving immunotherapy and to collect information about their treatment related efficacy, adverse events and health status to build a disease cohort database based on patient reports, and then analyze the risk factors affecting the efficacy, prognosis and adverse events of immunotherapy and the impact of immunotherapy on health status. It is expected to provide high-level evidence-based medical evidence for the selection of immunotherapy schemes for these patients, the precise prevention and health management of adverse events after immunotherapy, and the further improvement of survival prognosis of patients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Neoplasm | Malignant Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Solid tumor patients receiving immunotherapy for the first time were included in the study | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression-Free-Survival (PFS)
- timeFrame
- Two years
- description
- It refers to the time from randomization to disease progression
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria:
* Age range of subjects: the age of subjects is no less than 18 years old;
* Receiving any ICIs treatment or ICIs combined with other treatments;
* Soild malignant tumor proved by pathology (histology or cytology);
* First treatment with ICIs {including ICIs (first) combined with other treatments)};
* Any stage and treatment line (new auxiliary, auxiliary and advanced treatment)
* Willing to treat, and can come to the hospital regularly in the later period
Exclusion Criteria:
* Previous medical history of other malignant tumors;
* No pathology (histology or cytology) certificate;
* Having received ICIs or other immunotherapy in the past;
* Participated in clinical research in the past and may have applied ICIs or other immunotherapy;
* Weak treatment intention or long-term treatment in other hospitals/departmentsReferences
Publications (1)
- DERIVEDLi Y, Jia X, Liu M, Zhu Z, Qiao H, Jiang J, Li M, Xia W, Xu L, Zhang E, Wang W, Liu J, Xu R, Qi Y, Jing G, Bai Y, Jiao M, Hu S, Liu Z, Guo H, Jiang L. Impact of NSAID type, initiation timing, duration and dose on clinical outcomes of immunotherapy in NSCLC: a multicenter two-cohort study. J Immunother Cancer. 2026 Apr 1;14(4):e014360. doi: 10.1136/jitc-2025-014360. PMID 41922087